BenchSci continues its mission to create a community for scientists, publishers and suppliers by signing its first license for closed-access peer-reviewed content with the Federation of American Societies for Experimental Biology (FASEB).

13 September, 2017, Toronto CANADA, and Bethesda MD, USA — BenchSci, an AI discoverability platform that helps scientists design better experiments by decoding scientific papers and extracting usage data for biological compounds and related figures, has successfully completed its first license agreement, with FASEB. The agreement allows BenchSci to include FASEB’s flagship publication, The FASEB Journal (FJ), on the BenchSci platform to increase discoverability of relevant scientific compounds discussed within The FASEB Journal-published articles.

Founded in 2014, BenchSci has spent the last three years applying and refining its proprietary machine learning algorithm, decoding millions of Open Access (OA) scientific papers and over 3.7 million antibody products. BenchSci has further developed its platform with the assistance of numerous world-class academic institutions such as Georgetown University, University of Toronto, The University of Texas MD Anderson Cancer Center, and Baylor College of Medicine. BenchSci is now used in these institutions and many major pharmaceutical and biotechnology companies across North America.

However, OA papers only represent a subset of all scientific literature. Scientists generally use resources such as Google or PubMed that are missing non-OA information and tools that publishers might offer. To overcome this, BenchSci is working with publishers to make more of their content discoverable through its platform, without loss of readership or traffic to their sites. BenchSci’s machine learning technology pinpoints the exact information scientists look for within each paper and displays relevant figures for them to identify which articles to read. The figures act as a window into published articles, giving scientists more confidence that information relevant to their search parameters is located within. They can then visit the publisher’s website to access the full text.

“’Publish or perish’ is a driving force for scientists, but funding resources are limited. Scientists need to find the right products for their research, and fast. BenchSci prevents wasted time and resources by bringing scientists to the relevant information they need in a fraction of the time,” said Liran Belenzon, CEO of BenchSci. “The partnership between BenchSci and The FASEB Journal is a great first step to generating a more comprehensive database and allowing scientist to harness the power of the BenchSci platform to accelerate the pace of their research.”

Barbara Walker, Licensing Manager for The FASEB Journal said, “We are excited to be BenchSci’s first closed-access partner. This innovative tool will help scientists and researchers discover the appropriate biological compound(s) to design better experiments faster than previous generation technology platforms. Access to our world-class articles will only accelerate novel discoveries which, will benefit all.”

About BenchSci

BenchSci helps scientists design and conduct successful experiments. Built by a team of former bench scientists, BenchSci uses machine learning to decode millions of scientific papers and extract the crucial information scientists need. This reduces research hours and failed experiments, saving time and money, and speeding discoveries and medical breakthroughs. BenchSci is available free to academic scientists. Learn more at https://www.benchsci.com/.

Our goal is to help scientists find antibodies that have been proven to work by the scientific community, and therefore achieve scientific discoveries faster.

About The FASEB Journal

The FASEB Journal publishes international, transdisciplinary research covering all fields of biology at every level of organization: atomic, molecular, cell, tissue, organ, organismic and population. While the journal strives to include research that cuts across the biological sciences, it also considers submissions that lie within one field, but may have implications for other fields as well. The journal seeks to publish basic and translational research, but also welcomes reports of pre-clinical and early clinical research. In addition to research, review, and hypothesis submissions, The FASEB Journal also seeks perspectives, commentaries, book reviews, and similar content related to the life sciences in its Up Front section.

The journal has been covered by major news outlets, such as The New York Times, The Washington Post, The Chicago Tribune, U.S. News and World Report, Reuters, National Public Radio, Voice of America, ABC News, Scientific American, Bloomberg News, MSNBC, and BBC News.